PaperPlayer biorxiv biochemistry

beta-blocker reverses inhibition of beta-2 adrenergic receptor resensitization by hypoxia


Listen Later

Link to bioRxiv paper:
http://biorxiv.org/cgi/content/short/2020.09.17.301903v1?rss=1
Authors: Sun, Y., Gupta, M. K., Stenson, K., Mohan, M. L., Wanner, N., Asosinght, K., Erzurum, S., Naga Prasad, S. N.
Abstract:
Ischemia/hypoxia is major underlying cause for heart failure and stroke. Although beta-adrenergic receptor ({beta}AR) is phosphorylated in response to hypoxia, less is known about the underlying mechanisms. Hypoxia results in robust GRK2-mediated {beta}2AR phosphorylation but does not cause receptor internalization. However, hypoxia leads to significant endosomal-{beta}2AR phosphorylation accompanied by inhibition of {beta}2AR-associated protein phosphatase 2A (PP2A) activity impairing resensitization. Phosphoinositide 3-kinase {gamma} (PI3K{gamma}) impedes resensitization by phosphorylating endogenous inhibitor of protein phosphatase 2A, I2PP2A that inhibits PP2A activity. Hypoxia increased PI3K{gamma} activity leading to significant phosphorylation of I2PP2A resulting in inhibition of PP2A and consequently resensitization. Surprisingly, {beta}-blocker abrogated hypoxia-mediated {beta}2AR phosphorylation instead of phosphorylation in normoxia. Subjecting mice to hypoxia leads to significant cardiac dysfunction and {beta}2AR phosphorylation showing conservation of non-canonical hypoxia-mediated pathway in vivo. These findings provide mechanistic insights on hypoxia-mediated {beta}AR dysfunction which is rescued by {beta}-blocker and will have significant implications in heart failure and stroke.
Copy rights belong to original authors. Visit the link for more info
...more
View all episodesView all episodes
Download on the App Store

PaperPlayer biorxiv biochemistryBy Multimodal LLC